ARTL Stock Price, Artelo Biosciences Inc Quote, Chart

Market Summary

USD1.33+0.04

Market Closed

3.10%

ARTL Stock Price

View Fullscreen

ARTL RSI Chart

ARTL Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

2.4K

Price/Free Cashflow

-0.51

ARTL Price/Sales (Trailing)

ARTL Profitability

Return on Equity

-79.04%

Return on Assets

-71.22%

Free Cashflow Yield

-197.11%

ARTL Fundamentals

ARTL Revenue

Revenue (TTM)

2.0K

ARTL Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

7.97%

Earnings Growth (Qtr)

-25.48%

Breaking Down ARTL Revenue

52 Week Range

1.292.98

(Low)(High)

Last 7 days

-5.8%

Last 30 days

-16.1%

Last 90 days

-7.1%

Trailing 12 Months

-23.1%

How does ARTL drawdown profile look like?

ARTL Financial Health

Current Ratio

8.51

ARTL Investor Care

Shares Dilution (1Y)

13.03%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	3.0K	4.0K	3.0K	2.0K
2021	699.1K	559.7K	420.3K	141.4K
2020	1.3M	1.2M	978.0K	838.6K
2019	735.0K	852.6K	1.2M	1.3M
2018	331.9K	491.8K	585.1K	645.0K
2017	75.4K	98.7K	121.9K	220.1K
2016	0	0	28.9K	52.2K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Artelo Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 12, 2022	gorgas gregory d.	bought	4,800	4.00	1,200	pres, ceo, cfo, treas & secr
Aug 11, 2022	gorgas gregory d.	bought	4,836	4.03	1,200	pres, ceo, cfo, treas & secr
Apr 16, 2021	gorgas gregory d.	bought	9,809	1.154	8,500	pres, ceo, cfo, treas & secr
May 15, 2020	gorgas gregory d.	bought	5,071	1.2076	4,200	pres, ceo, cfo, treas & secr
May 04, 2020	matsui connie	bought	50,000	1.2	41,667	-
May 04, 2020	gorgas gregory d.	bought	5,000	1.2	4,167	pres, ceo, cfo, treas & secr
Nov 04, 2019	gorgas gregory d.	bought	5,303	2.2098	2,400	pres, ceo, cfo, treas & secr
Nov 01, 2019	gorgas gregory d.	bought	5,701	2.2807	2,500	pres, ceo, cfo, treas & secr
Oct 31, 2019	gorgas gregory d.	bought	4,874	1.9499	2,500	pres, ceo, cfo, treas & secr
Oct 30, 2019	gorgas gregory d.	bought	5,186	1.9948	2,600	pres, ceo, cfo, treas & secr

Which funds bought or sold ARTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-104	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-4.00	-	-%
Feb 14, 2024	Verition Fund Management LLC	unchanged	-	-230	1,089	-%
Feb 13, 2024	NewEdge Advisors, LLC	new	-	1.00	1.00	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-	6.00	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-1.00	28.00	-%
Feb 13, 2024	FMR LLC	sold off	-100	-29.00	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	124	3,595	6,724	-%

Are Funds Buying or Selling ARTL?

Are funds buying ARTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARTL

No. of Funds

Unveiling Artelo Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2022	iroquois capital management, llc	0.24%	1e+05	SC 13G/A
Feb 09, 2022	parian global management lp	0%	0	SC 13G/A
Feb 04, 2022	hudson bay capital management lp	0%	0	SC 13G/A
Mar 01, 2021	parian global management lp	7.6%	1,199,738	SC 13G
Feb 16, 2021	cvi investments, inc.	4.9%	793,672	SC 13G/A
Feb 10, 2021	bigger capital fund l p	2.8%	450,000	SC 13G/A
Feb 08, 2021	hudson bay capital management lp	5.74%	920,000	SC 13G
Feb 05, 2021	kingsbrook partners lp	4.99%	8e+05	SC 13G/A
Jan 15, 2021	alpha capital anstalt	4.99%	784,008	SC 13G/A
Jan 13, 2021	empery asset management, lp	4.99%	920,000	SC 13G

Recent SEC filings of Artelo Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	S-8	Employee Benefits Plan
Mar 25, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Artelo Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Artelo Biosciences Inc News

Latest updates

Artelo Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-	-	-	-	1.00	1.00	1.00	1.00	76.00	151	226	198	195	193	304	215	266	433	354	210	167	121
Operating Expenses	-6.8%	3,240	3,476	2,394	2,471	1,946	4,042	2,552	2,245	1,517	2,251	1,868	1,436	1,028	951	1,371	1,336	953	941	-	-	-
S&GA Expenses	-36.2%	1,116	1,750	1,316	1,415	1,482	2,098	1,279	1,211	697	1,074	1,006	841	1,541	389	434	403	286	403	-	-	-
R&D Expenses	23.1%	2,124	1,726	1,078	1,056	464	1,944	1,273	1,034	933	951	663	595	272	259	721	667	234	184	-	-	-
Interest Expenses	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	8.0%	-3,073	-3,339	-2,330	-2,449	-1,965	-4,035	-2,548	-2,245	-1,517	-2,249	-1,865	-1,435	-1,027	-951	-1,370	-1,306	-845	-344	-	-	-
Net Income Margin	7.9%	-4.64	-5.04	-59.28*	-30.41*	-19.93*	-14.34*	-11.87*	-9.17*	-7.14*	-7.46*	-6.21*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-13.2%	-2,596	-2,293	-1,696	-1,966	-2,053	-2,667	-1,926	-1,055	-1,055	-1,742	-945	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-15.8%	13,043	15,499	16,877	18,478	20,424	22,415	24,405	26,704	28,251	29,004	12,635	12,340	13,445	9,539	4,376	3,494	4,152	5,548	6,483	1,153	484
Current Assets	-18.2%	10,980	13,428	14,602	16,386	18,322	20,303	22,282	24,589	24,609	25,355	10,317	10,300	11,405	7,500	2,337	1,453	2,111	3,508	4,443	1,152	484
Cash Equivalents	6.7%	2,815	2,639	5,719	6,916	6,888	7,136	12,122	10,350	12,162	14,047	6,629	10,052	10,706	7,389	2,142	1,279	1,983	3,375	4,424	286	-
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	63*	124*	185*	246*	1.00	2.00	598*	721*	857*	414*
Liabilities	40.2%	1,291	921	609	840	1,021	512	567	924	1,084	718	593	570	547	524	501	-	-	-	-	-	-
Current Liabilities	40.2%	1,291	921	603	825	998	480	527	875	1,027	659	526	424	589	486	501	268	444	585	1,022	1,019	1,176
Shareholder's Equity	-19.4%	11,752	14,578	16,268	17,638	19,403	21,903	23,838	25,780	27,167	28,286	12,042	11,916	12,856	9,054	3,875	3,225	3,708	4,963	5,460	134	-
Retained Earnings	-8.3%	-40,310	-37,237	-34,788	-33,189	-31,021	-27,682	-25,352	-22,903	-20,938	-19,451	-16,903	-15,015	-12,766	-10,900	-9,466	-8,438	-7,487	-6,117	-4,810	-3,965	-3,620
Additional Paid-In Capital	0.5%	52,262	52,011	51,254	51,029	50,675	49,970	49,324	48,705	48,120	47,718	28,925	26,859	25,552	19,891	13,272	11,609	11,176	11,071	10,278	4,108	2,923
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	2.00	2.00	1.00	1.00	1.00	1.00	886*	792*	646*	415*
Shares Outstanding	0.8%	3,189	3,162	2,856	2,856	2,856	2,856	2,840	2,820	2,820	2,820	1,635	1,543	1,481	-	-	-	-	-	-	-	-
Float	-	-	-	5,630	-	-	-	13,685	-	-	-	-	-	39,891	-	-	-	2,970	-	-	-	12,812

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q4	2021Q3	2021Q3	2021Q2	2021Q2	2021Q1	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-44.1%	-2,596	-1,802	-1,623	-2,186	-2,293	-1,696	-1,966	-2,053	-2,667	-1,926	-	-1,055	-	-	-1,742	-945	-1,874	-1,320	-872	-1,020	-1,402
Share Based Compensation	-1.4%	219	222	225	354	608	607	619	624	934	571	502	-	609	-	519	323	70.00	51.00	55.00	53.00	105
Cashflow From Investing	249.6%	2,741	-1,832	399	2,199	1,796	-3,080	3,985	257	-10,033	-8,878	-	-	-1,289	-	-2,044	544	-1,055	-	1.00	-	-
Cashflow From Financing	-94.0%	32.00	535	-	-	134	-	-134	-	18,261	18,262	-	890	-	-	6,009	5,320	6,578	6,579	1,710	283	2.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARTL Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES
General and administrative	$ 4,234	$ 5,963
Research and development	5,696	4,324
Total Operating Expenses	9,930	10,287
Loss from Operations	(9,930)	(10,287)
OTHER INCOME (EXPENSE)
Interest income	0	2
Interest expense	0	(5)
Net change in fair value of trading marketable securities	641	207
Total other income	641	204
Provision for income taxes	0	0
NET LOSS	(9,289)	(10,083)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized (loss) gain on available-for-sale securities	0	(24)
Foreign currency translation adjustments	51	(212)
Total Other Comprehensive Income (Loss)	51	(236)
TOTAL COMPREHENSIVE LOSS	$ (9,238)	$ (10,319)
Basic and Diluted Loss per Common Share	$ (3.14)	$ (3.56)
Basic and Diluted Weighted Average Common Shares Outstanding	2,960	2,833

ARTL Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 2,815	$ 6,888
Trading marketable securities	7,611	9,150
Available-for-sale securities (amortized cost of $0 and $1,502, respectively)	0	1,495
Prepaid expenses and other current assets	554	789
Total Current Assets	10,980	18,322
Operating lease right-of-use assets	21	60
Intangible asset	2,039	2,039
Other assets	3	3
TOTAL ASSETS	13,043	20,424
Current Liabilities
Accounts payable and accrued liabilities	1,238	905
Due to related parties	30	53
Operating lease liabilities - current portion	23	40
Total Current Liabilities	1,291	998
Operating lease liabilities	0	23
TOTAL LIABILITIES	1,291	1,021
STOCKHOLDERS' EQUITY
Preferred Stock, par value $0.001, 416,667 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common Stock, par value $0.001, 50,000,000 shares authorized, as of December 31, 2023 and December 31, 2022 3,188,959 and 2,855,688 shares issued and outstanding as of December 31, 2023 and December 31, 2022	3	3
Additional paid-in capital	52,262	50,675
Accumulated deficit	(40,310)	(31,021)
Accumulated other comprehensive loss	(203)	(254)
TOTAL STOCKHOLDERS' EQUITY	11,752	19,403
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 13,043	$ 20,424

About Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

CEO	Mr. Gregory D. Gorgas M.B.A.
WEBSITE	artelobio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Artelo Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Artelo Biosciences Inc? What does ARTL stand for in stocks?

ARTL is the stock ticker symbol of Artelo Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artelo Biosciences Inc (ARTL)?

As of Tue May 07 2024, market cap of Artelo Biosciences Inc is 4.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers.

What is the fair value of ARTL stock?

You can check ARTL's fair value in chart for subscribers. The fair value of Artelo Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artelo Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artelo Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ARTL is over valued or under valued. Whether Artelo Biosciences Inc is cheap or expensive depends on the assumptions which impact Artelo Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARTL.

What is Artelo Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ARTL's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 2.42 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARTL PE ratio will change depending on the future growth rate expectations of investors.